Consultation on a proposed Pathogens of Interest List

From Health Canada

Current status: Closed

This consultation ran from April 17, 2018 to July 1, 2018.

Antimicrobial resistant (AMR) infections are becoming more frequent and increasingly difficult to treat. As a result, AMR is now recognized as a growing public health threat in Canada and around the world. In order to combat this threat Health Canada proposes to use a Pathogens of Interest List, which would serve two purposes:

  1. Inform sponsors of the bacterial pathogens in most urgent need of innovative therapeutic drugs and/or devices in Canada; and
  2. Guide the development of new tools and policy approaches by Health Canada.

You are invited to review the proposed Pathogens of Interest List and provide written comments.

Join in: How to participate

  1. Read our Notice - Update on Health Canada's efforts to support innovative human therapeutic products to combat antimicrobial resistance (AMR) and consultation on a proposed Pathogens of Interest List
  2. Provide your comments on the following questions:
    1. Will the proposed Health Canada Pathogens of Interest List assist the development by sponsors of innovative priority therapies to combat AMR?
    2. Should any pathogens be added to or removed from the Proposed List to better reflect the Canadian context?
    3. How could this List be used to further stimulate the submission to Health Canada of new health products and facilitate their regulatory approvals?
    4. What new regulatory approaches or policy tools could be adopted that would facilitate a greater access to safe, effective and high quality therapies to help address the AMR issue?

Send us an email

Send an email to with your input or comments.

Participate by mail

Send a letter with your input or comments to the address in the contact information section.

Goals of the consultation

There are two goals to this consultation.

  1. To review and confirm the proposed Pathogens of Interest list, and
  2. Receive feedback on potential improvements to the regulatory review process for
    1. therapeutic drugs, and(or)
    2. medical devices that target important pathogens for public health

Who is the focus of this consultation

We're seeking input from all interested parties, including:

  • industry members and associated groups
  • health professionals and associated groups
  • academia and associated groups

Contact us

Bureau of Gastroenterology Infection and Viral Diseases
Therapeutic Products Directorate
Health Products and Food Branch
Address Locator: 0202B
Health Canada
Ottawa, Ontario
K1A 0K9

Telephone: 613-941-2566
Fax: 613-941-1183

Page details

Date modified: